Protein Kinase Inhibitors

"Protein Kinase Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Agents that inhibit PROTEIN KINASES.

Descriptor ID	D047428
MeSH Number(s)	D27.505.519.389.755
Concept/Terms	Protein Kinase Inhibitors Protein Kinase Inhibitors Inhibitors, Protein Kinase Kinase Inhibitors, Protein

Below are MeSH descriptors whose meaning is more general than "Protein Kinase Inhibitors".

Chemicals and Drugs [D]
Chemical Actions and Uses [D27]
Pharmacologic Actions [D27.505]
Molecular Mechanisms of Pharmacological Action [D27.505.519]
Enzyme Inhibitors [D27.505.519.389]
Protein Kinase Inhibitors [D27.505.519.389.755]

Below are MeSH descriptors whose meaning is related to "Protein Kinase Inhibitors".

Below are MeSH descriptors whose meaning is more specific than "Protein Kinase Inhibitors".

Protein Kinase Inhibitors
Janus Kinase Inhibitors

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Protein Kinase Inhibitors" by people in this website by year, and whether "Protein Kinase Inhibitors" was a major or minor topic of these publications.

Bar chart showing 98 publications over 23 distinct years, with a maximum of 9 publications in 2014

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1995	2	0	2
1998	0	1	1
2003	0	2	2
2004	1	0	1
2005	1	1	2
2006	3	0	3
2007	0	3	3
2008	3	4	7
2009	2	3	5
2010	1	3	4
2011	4	3	7
2012	2	6	8
2013	0	6	6
2014	4	5	9
2015	1	3	4
2016	3	5	8
2017	0	1	1
2018	2	3	5
2019	3	5	8
2020	2	2	4
2021	2	1	3
2022	0	3	3
2023	0	2	2

Below are the most recent publications written about "Protein Kinase Inhibitors" by people in Profiles.

Peng X, Guo S, Zheng S, Hossain A, Zhang C, Mottamal M, Skripnikova E, Ma P, Martinez-Carter K, Zhang Q, Abedin F, Huckaba T, Wang G. Discovery of Oral Degraders of the ROS1 Fusion Protein with Potent Activity against Secondary Resistance Mutations. J Med Chem. 2024 Oct 24; 67(20):18098-18123.

View in: PubMed
Gallo PM, Chain RW, Xu J, Whiteman LM, Palladino A, Caricchio R, Costa-Reis P, Sullivan KE, Gallucci S. EGFR-ErbB2 dual kinase inhibitor lapatinib decreases autoantibody levels and worsens renal disease in Interferon a-accelerated murine lupus. Int Immunopharmacol. 2024 Oct 25; 140:112692.

View in: PubMed
Orlandi P, Banchi M, Vaglini F, Carli M, Aringhieri S, Bandini A, Pardini C, Viaggi C, Lai M, Al? G, Ottani A, Vandini E, Guidi P, Bernardeschi M, La Rocca V, Francia G, Fontanini G, Pistello M, Frenzilli G, Giuliani D, Scarselli M, Bocci G. Melanocortin receptor 4 as a new target in melanoma therapy: Anticancer activity of the inhibitor ML00253764 alone and in association with B-raf inhibitor vemurafenib. Biochem Pharmacol. 2024 01; 219:115952.

View in: PubMed
Ingle K, LaComb JF, Graves LM, Baines AT, Bialkowska AB. AUM302, a novel triple kinase PIM/PI3K/mTOR inhibitor, is a potent in vitro pancreatic cancer growth inhibitor. PLoS One. 2023; 18(11):e0294065.

View in: PubMed
Gonzalez MA, Olivas IM, Bencomo-Alvarez AE, Rubio AJ, Barreto-Vargas C, Lopez JL, Dang SK, Solecki JP, McCall E, Astudillo G, Velazquez VV, Schenkel K, Reffell K, Perkins M, Nguyen N, Apaflo JN, Alvidrez E, Young JE, Lara JJ, Yan D, Senina A, Ahmann J, Varley KE, Mason CC, Eide CA, Druker BJ, Nurunnabi M, Padilla O, Bajpeyi S, Eiring AM. Loss of G0/G1 switch gene 2 (G0S2) promotes disease progression and drug resistance in chronic myeloid leukaemia (CML) by disrupting glycerophospholipid metabolism. Clin Transl Med. 2022 12; 12(12):e1146.

View in: PubMed
Kalra R, Chen CH, Wang J, Salam AB, Dobrolecki LE, Lewis A, Sallas C, Yates CC, Gutierrez C, Karanam B, Anurag M, Lim B, Ellis MJ, Kavuri SM. Poziotinib Inhibits HER2-Mutant-Driven Therapeutic Resistance and Multiorgan Metastasis in Breast Cancer. Cancer Res. 2022 08 16; 82(16):2928-2939.

View in: PubMed
Messeha SS, Nezami MA, Hager S, Soliman KFA. A Rare Presentation of a Non-Asian Female With Metastatic Non-small-cell Lung Cancer Harboring EGFR L747P Mutation With Clinical Response to Multi-targeted Epigenetic and EGFR Inhibition. Anticancer Res. 2022 Jan; 42(1):441-447.

View in: PubMed
Borrero-Garc?a LD, Del Mar Maldonado M, Medina-Vel?zquez J, Troche-Torres AL, Velazquez L, Grafals-Ruiz N, Dharmawardhane S. Rac inhibition as a novel therapeutic strategy for EGFR/HER2 targeted therapy resistant breast cancer. BMC Cancer. 2021 Jun 01; 21(1):652.

View in: PubMed
Napoleon JV, Singh S, Rana S, Bendjennat M, Kumar V, Kizhake S, Palermo NY, Ouellette MM, Huxford T, Natarajan A. Small molecule binding to inhibitor of nuclear factor kappa-B kinase subunit beta in an ATP non-competitive manner. Chem Commun (Camb). 2021 May 11; 57(38):4678-4681.

View in: PubMed
Jo T, Michihata N, Yamana H, Morita K, Ishimaru M, Yamauchi Y, Hasegawa W, Urushiyama H, Uda K, Matsui H, Fushimi K, Yasunaga H, Nagase T. Risk of drug-induced interstitial lung disease in hospitalised patients: a nested case-control study. Thorax. 2021 12; 76(12):1193-1199.

View in: PubMed

People

Explore

Similar Concepts

Top Journals